ReviewDrug design, development and therapy2026
Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide, and metabolic dysfunction is increasingly recognized as an important component of its pathophysiology. Clinical evidence supports a role for dysregulated lipid and glucose metabolism in atherosclerosis, heart failure, and cardiometabolic disease, while alterations in amino acid metabolism, mitochondrial energetics, redox signaling, and immunometabolic pathways are supported by growing experimental and observational evidence. Advances in metabolomics, systems biology, and multi-omics approaches have further identified metabolic signatures associated with cardiovascular phenotypes and have provided new insights into pathways regulating endothelial function, vascular inflammation, oxidative stress, and cardiac remodeling. This review synthesizes established clinical evidence and emerging experimental findings on metabolic mechanisms in CVD, with particular emphasis on their potential therapeutic and biomarker implications. We discuss current and investigational strategies targeting lipid and glucose metabolism, mitochondrial dysfunction, oxidative stress, and immunometabolic signaling, while distinguishing clinically validated approaches from those that remain primarily preclinical or hypothesis-generating. Key translational challenges include the complexity and tissue specificity of metabolic networks, limitations of existing experimental models, potential safety liabilities, and the need for longitudinal studies integrating metabolic and clinical phenotypes. Finally, we examine how metabolomics, AI, organ-on-chip models, and systems-level approaches could improve target identification, patient stratification, and therapeutic development. These advances provide a framework for translating mechanistic insights into metabolism-informed cardiovascular therapies and biomarkers, while highlighting the evidence gaps that must be addressed before broader clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.